Office Action Predictor
Last updated: April 16, 2026
Application No. 18/660,814

MICROFRACTURE APPARATUSES AND METHODS

Non-Final OA §102§103
Filed
May 10, 2024
Examiner
YANG, ANDREW
Art Unit
3775
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Anika Therapeutics, INC.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
99%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1078 granted / 1284 resolved
+14.0% vs TC avg
Strong +18% interview lift
Without
With
+17.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
40 currently pending
Career history
1324
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
37.9%
-2.1% vs TC avg
§112
13.6%
-26.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1284 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 78-83, 85-89, 92, 96-98, 102, 104, 105 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Sikora et al. (U.S. Publication No. 2013/0317506). The applied reference has a common Inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Sikora et al. substantially discloses all elements of claims 78-83, 85-89, 92, 96-98, 102, 104, 105 as can be seen in the figures and defined in the specification. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 78, 79, 83, 85-87, 92, 96, 102, 104, 105 is/are rejected under 35 U.S.C. 103 as being unpatentable over Smith and Nephew, INC (WO2012/103459). Smith and Nephew discloses a method of forming a microfracture in subchondral bone of a patient (page 5, line 2), the method comprising: disposing the microfracture apparatus (100) comprising a cannula (120) and a penetrator (106), the penetrator configured to pass at least partially through a longitudinal passageway of the cannula to a location adjacent to the subchondral bone (Figure 4); and advancing the penetrator relative to the cannula, substantially without rotation of the penetrator (page 8, paragraph beginning with, “In some implementations”). Smith and Nephew, INC fails to disclose that the penetration depth is greater than 5mm. It would have been obvious to one having ordinary skill in the art at the time the invention was made to perform the method so that the penetration depth is greater than 5mm, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980). Regarding claim 79, the method further comprising: repeating the steps of disposing and advancing to form a plurality of microfractures in the subchondral bone (Page 1, last line to page 2, lines 1, 2, “a series of channels can be formed). Regarding claim 83, the cannula comprises a handle (136) having an indicator indicative of the position of the distal portion of the cannula. (the position of the handle itself is an indicator since it is known where the handle is in relation to the distal portion of the cannula). Regarding claim 85, the penetrator is advanced manually (page 8, paragraph beginning with, “In some implementations”). Regarding claim 86, the position of the second end of the cannula relative to the bone is substantially constant while advancing the penetrator (Figure 7A). Regarding claim 87, the penetrator has an enlarged head (106a), and the penetration distance is limited by the enlarged head contacting the cannula. Regarding claim 92, the distal end (114) of the penetrator is pointed (Figure 1B). Regarding claim 96, the penetrator (106) includes a primary portion (most of the length of penetrator 106) and a penetration portion (tapered portion leading to 114) disposed between the primary portion and the distal end, the first transverse dimension is in the penetration portion, and a second transverse dimension is between the first transverse dimension and the primary portion (each section has a transverse dimension). Regarding claim 102, the distal end (114) includes a pointed tip (Figure 1B) with a cross-sectional shape defined by a tip angle of 60 degrees or greater (it can be seen that the tip angle is substantially 90 degrees). Regarding claim 104, the tip angle is greater than 90 degrees (page 6, Lines 1-2). Regarding claim 105, the tip angle is greater than 120 degrees (page 6, Lines 1-2, since there is no upper limit to the statement, “in some cases, the angle alpha can be greater than 90 degrees, it is considered that all angles above 90 degrees, including those above 120 degrees are considered). Allowable Subject Matter Claims 106 and 107 allowed. The following is a statement of reasons for the indication of allowable subject matter: The prior art alone or in combination fails to disclose a method of microfracture surgery by disposing a cannula adjacent an articular surface, inserting a penetrator into the canula such that it is moved from a retracted position to an extended position to form a microfracture in the subchondral bone. The penetrator is removed from the cannula and a solution is injected through the cannula to the microfracture. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW YANG whose telephone number is (571)272-3472. The examiner can normally be reached 9:00 - 9:00 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Truong can be reached at 571-272-4705. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW YANG/Primary Examiner, Art Unit 3775
Read full office action

Prosecution Timeline

May 10, 2024
Application Filed
Aug 22, 2025
Non-Final Rejection — §102, §103
Apr 01, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594082
SURGICAL CUTTING TOOL
2y 5m to grant Granted Apr 07, 2026
Patent 12589004
Systems and Methods for Patient-Specific Total Disc Replacement
2y 5m to grant Granted Mar 31, 2026
Patent 12588913
BONE GRAFT HARVESTING APPARATUS
2y 5m to grant Granted Mar 31, 2026
Patent 12588916
ANKLE REPLACEMENT SYSTEM AND METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12582410
Surgical Sagittal Blade Cartridge
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
99%
With Interview (+17.7%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 1284 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month